Meeting Overview - The third extraordinary general meeting of shareholders was held on August 15, 2025, at the company's conference room in Zhengzhou [2] - The meeting was convened by the board of directors and chaired by Chairman Yin Hui, using a combination of on-site and online voting [2][3] - All resolutions passed during the meeting were in compliance with the Company Law and the company's articles of association [2][5] Resolutions Passed - The proposal to abolish the supervisory board and amend the articles of association was approved [3] - Amendments to the rules of procedure for shareholder meetings, board meetings, and independent director work systems were also approved [4] - The election of the tenth board of directors, including both non-independent and independent directors, was conducted [4] Board of Directors Composition - The tenth board of directors consists of Chairman Wang Rongtao, Vice Chairman Li Jingliang, and other members including independent directors and a worker representative [30][31] - The board's term is set for three years, starting from the date of approval by the shareholders' meeting [31] Management Appointments - Li Jingliang was appointed as the General Manager, with other key appointments including Su Fengshan as Executive Vice General Manager and Zhao Hailin as Financial Officer [34] - The board secretary is Li Nianyun, and the securities affairs representative is Wu Ting, with all appointments aligned with the board's term [34][35] Legal Compliance - The meeting and its resolutions were witnessed by Henan Qianwen Law Firm, confirming that all procedures adhered to relevant laws and regulations [5][30]

Core Viewpoint - TaiLong Pharmaceutical's stock price increased by 3.24% to 7.00 CNY, reflecting positive market sentiment and trading activity [1] Company Overview - TaiLong Pharmaceutical operates in the pharmaceutical manufacturing industry, focusing on three core business segments: drug formulations, traditional Chinese medicine pieces, and pharmaceutical research and development services [1] - The company was established in 1993 and became the first listed pharmaceutical company in Henan Province when it went public on the Shanghai Stock Exchange in 1999 [1] Recent Developments - On August 15, TaiLong Pharmaceutical announced the completion of its board of directors' re-election and the appointment of senior management and securities affairs representatives [1] - The company elected five non-independent directors and three independent directors, with Wang Rongtao being appointed as the chairman of the tenth board of directors [1] - Wang Rongtao has previously held positions as the secretary and chairman of Zhengzhou High-tech Construction Group Co., Ltd., and currently serves as a member of the party branch and vice chairman of Zhengzhou High-tech Science City Investment Development Group Co., Ltd. [1] Stock Performance - The stock opened at 6.73 CNY, reached a high of 7.20 CNY, and a low of 6.64 CNY during the trading session [1] - The trading volume was 548,988 hands, with a total transaction value of 381 million CNY [1]

证券日报网讯 8月15日晚间，太龙药业发布公告称，公司2025年第三次临时股东大会审议通过了《关于 取消监事会并修订的议案》等多项议案。 （文章来源：证券日报） ...

Core Viewpoint - Tai Long Pharmaceutical announced the approval of multiple proposals, including the election of the chairman of the board at the first meeting of its tenth board of directors [2] Group 1 - The company held its first meeting of the tenth board of directors on August 15 [2] - The board approved the proposal for the election of the chairman [2]

Group 1 - The company announced that it will hold a staff representative meeting on August 15, 2025 [1] - Chen Fengyun has been democratically elected as the employee representative director of the company's tenth board of directors [1]

太龙药业（SH 600222，收盘价：7元）8月15日晚间发布公告称，公司第十届第一次董事会会议于2025 年8月15日在公司一楼会议室以现场结合通讯的方式召开。会议审议了《关于聘任公司董事会秘书的议 案》等文件。 2024年1至12月份，太龙药业的营业收入构成为：医药制造业占比79.38%，医药研发占比13.65%，医药 流通占比6.71%，其他业务占比0.27%。 （文章来源：每日经济新闻） ...

Core Points - The board of directors of Henan Tailong Pharmaceutical Co., Ltd. held its first meeting of the tenth session on August 15, 2025, with all nine directors present [1][2][3] - The meeting approved the election of Wang Rongtao as the chairman of the board, with a unanimous vote of 9 in favor [1] - Li Jingliang was elected as the vice chairman of the board, also with a unanimous vote of 9 in favor [2] - The board established various specialized committees, including the Strategy and Development Committee, Audit Committee, Nomination Committee, and Compensation and Assessment Committee, with all members elected unanimously [2] - Li Jingliang was appointed as the general manager of the company, with a unanimous vote of 9 in favor [3] - Su Fengshan was appointed as the executive vice general manager, and three others were appointed as vice general managers, all with unanimous approval [3] - Zhao Hailin was appointed as the financial officer, and Li Nianyun was appointed as the board secretary, both with unanimous votes [4] - Wu Ting was appointed as the securities affairs representative, also with unanimous approval [4]

河南仟问律师事务所关于河南太龙药业股份有限公司 2025 年第三次临时股东大会的法律意见书 仟问律师事务所 CHAINWINLAWFIRM 中国郑州市平安大道 189 号正商环湖国际 5、12 层(450018) 网址(URL)：http://www.chainwinlaw.com 电邮(E-mail):qwlss@126.com 仟见字【2025】371 号 关于河南太龙药业股份有限公司 致：河南太龙药业股份有限公司 河南仟问律师事务所（以下简称"本所"）接受河南太龙药业股份有限公司（以 下简称"公司"）的委托，委派本所律师出席公司 2025 年第三次临时股东大会（以 下简称"本次股东大会"），就本次股东大会的召集和召开程序，出席本次股东大 会人员的资格，审议事项及其表决程序等相关事宜出具法律意见。 为出具本法律意见书，本所律师审查了公司提供的有关本次股东大会的文件、 材料。公司保证其向本所提供的文件和材料是完整、真实和有效的，且一切足以 影响本法律意见书的事实、文件和材料均已向本所披露，无任何隐瞒、疏漏之处。 （以下简称"《公司法》"）、 有鉴于此，本所律师根据《中华人民共和国公司法》 《中华人民共和国证 ...

Meeting Overview - The shareholders' meeting of Henan Tailong Pharmaceutical Co., Ltd. was held on August 15, 2025, at the company's conference room in Zhengzhou High-tech Industrial Development Zone [1] - The meeting was convened by the board of directors and chaired by Chairman Yin Hui, utilizing a combination of on-site and online voting methods [1][3] - All procedures for convening and conducting the meeting complied with the Company Law and the company's articles of association, ensuring the legality and validity of the resolutions [3][4] Voting Results - Non-cumulative voting resolutions were all passed with significant support, including: - A total of 151,054,504 votes (98.4456%) in favor, 1,343,931 votes (0.8759%) against, and 1,041,100 votes (0.6785%) abstaining for the first resolution [1] - Similar high approval rates were observed for subsequent resolutions, with votes in favor consistently above 98% [1][2] - Cumulative voting for the election of directors also showed strong support, with 151,676,834 votes (98.8512%) in favor for the election of non-independent directors [2] Legal Compliance - The meeting's resolutions were confirmed to be legally valid, as they met the required thresholds for special and ordinary resolutions, with over two-thirds and half of the voting rights respectively [3][4] - Legal representatives confirmed that all aspects of the meeting adhered to relevant laws and regulations, ensuring the integrity of the proceedings [4]

Core Viewpoint - The announcement details the election of a new employee representative director, Chen Fengyun, at Henan Tailong Pharmaceutical Co., Ltd., as part of the company's governance structure [1][2]. Group 1: Election Announcement - Henan Tailong Pharmaceutical Co., Ltd. will elect Chen Fengyun as an employee representative director during the third extraordinary general meeting of shareholders in 2025 [1]. - Chen Fengyun will join the eight directors elected at the same meeting to form the company's tenth board of directors, with a term aligned with that board [1]. Group 2: Qualifications of the New Director - Chen Fengyun meets all legal and regulatory requirements for the position of director, with no disqualifications under the Company Law or the company's articles of association [1]. - There are no current restrictions on Chen Fengyun's ability to serve as a director, including any sanctions from the China Securities Regulatory Commission or recognition by stock exchanges as unsuitable for the role [1]. Group 3: Background of Chen Fengyun - Chen Fengyun, born in January 1978, holds a bachelor's degree and is a member of the Communist Party of China, as well as a senior accountant [2]. - She has held various positions within the company, including Deputy Manager of the Planning Audit Department and Director of the Budget and Financial Management Center [2].